SCHEMBL30954055

SCHEMBL30954055

COc1c(Cl)cc2c(c1C(=O)O)OCCN2CCc1cc(F)cc(F)c1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
DRD3 P35462 9/20 0.33
DRD2 P14416 7/20 0.33
DRD4 P21917 7/20 0.33
HTR1A P08908 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
DRD1 P21728 6/20 0.33
DRD5 P21918 6/20 0.33
KCNA3 P22001 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27433820 1.00 KDM4E (0.34) KDM4EALDH1A1HSD17B10DRD3DRD2
SCHEMBL27435374 0.88 KCNA3 (0.43) KDM4EALDH1A1HSD17B10DRD3DRD2
SCHEMBL30954054 0.88 KCNA3 (0.43) KDM4EALDH1A1HSD17B10DRD3DRD2
SCHEMBL27434671 0.86 TP53 (0.40) KDM4EALDH1A1HSD17B10KCNA3MEN1
SCHEMBL30954057 0.86 TP53 (0.40) KDM4EALDH1A1HSD17B10KCNA3MEN1
SCHEMBL27435335 0.82 KDM4E (0.40) KDM4EALDH1A1HSD17B10DRD3DRD2
SCHEMBL30954160 0.82 KDM4E (0.40) KDM4EALDH1A1HSD17B10DRD3DRD2
SCHEMBL27435528 0.81 KCNA3 (0.41) KDM4EALDH1A1HSD17B10DRD3DRD2
SCHEMBL27435364 0.80 KCNA3 (0.42) KDM4EALDH1A1DRD3DRD2DRD4
SCHEMBL30954067 0.79 TP53 (0.42) KDM4EALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP claimed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO claimed
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed